Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $25.57 Average Price Target from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given an average rating of “Moderate Buy” by the nine analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $27.4286.

A number of research analysts have weighed in on STOK shares. Jefferies Financial Group started coverage on Stoke Therapeutics in a research note on Friday, July 18th. They set a “buy” rating and a $30.00 price target on the stock. Chardan Capital reissued a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Weiss Ratings reissued a “sell (d+)” rating on shares of Stoke Therapeutics in a research note on Wednesday. Wedbush increased their price target on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 13th. Finally, Needham & Company LLC increased their price target on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday.

Stoke Therapeutics Stock Performance

STOK stock opened at $30.19 on Wednesday. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $32.40. The stock’s 50 day moving average price is $20.97 and its 200 day moving average price is $13.83. The firm has a market cap of $1.65 billion, a P/E ratio of 35.52 and a beta of 1.24.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.The firm had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million. On average, research analysts predict that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Insiders Place Their Bets

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 45,996 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $20.13, for a total transaction of $925,899.48. Following the transaction, the director owned 91,585 shares of the company’s stock, valued at $1,843,606.05. This represents a 33.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Barry Ticho sold 5,501 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total value of $109,304.87. Following the sale, the insider owned 18,469 shares of the company’s stock, valued at approximately $366,979.03. The trade was a 22.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 185,180 shares of company stock valued at $4,129,406 in the last quarter. 9.50% of the stock is currently owned by company insiders.

Institutional Trading of Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Stoke Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company’s stock worth $18,515,000 after buying an additional 53,004 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Stoke Therapeutics by 7.9% during the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock worth $26,111,000 after buying an additional 168,771 shares during the last quarter. Siren L.L.C. increased its holdings in shares of Stoke Therapeutics by 12.4% during the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock worth $14,945,000 after buying an additional 247,347 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after buying an additional 293,072 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Stoke Therapeutics by 7.9% during the 2nd quarter. Geode Capital Management LLC now owns 972,921 shares of the company’s stock worth $11,044,000 after buying an additional 70,935 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.